Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 346 to 360 of 520 results for meta analysis

  1. PROPEL sinus implants for maintaining sinus patency after surgery (MIB253)

    NICE has developed a medtech innovation briefing (MIB) on PROPEL sinus implants for maintaining sinus patency after surgery .

    Medtech innovation briefing
    Published
    9 February 2021

  2. Ustekinumab for treating moderately to severely active ulcerative colitis (TA633)

    Evidence-based recommendations on ustekinumab (Stelara) for treating moderately to severely active ulcerative colitis in adults.

    Technology appraisal guidance
    Published
    17 June 2020
    View recommendations

    Sections for TA633

  3. Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)

    Evidence-based recommendations on risankizumab (Skyrizi) for treating active psoriatic arthritis in adults.

    Technology appraisal guidance
    Published
    13 July 2022
    View recommendations

    Sections for TA803

  4. Technology appraisal committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  5. Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)

    Evidence-based recommendations on finerenone (Kerendia) for stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults.

    Technology appraisal guidance
    Published
    23 March 2023
    View recommendations

    Sections for TA877

  6. Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)

    Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.

    Technology appraisal guidance
    Last updated
    1 May 2025
    View recommendations

    Sections for TA878

  7. Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)

    Evidence-based recommendations on andexanet alfa (Ondexxya) for reversing anticoagulation form apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding.

    Technology appraisal guidance
    Last updated
    15 January 2025
    View recommendations

    Sections for TA697

  8. Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)

    Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and imatinib (Glivec) for untreated chronic myeloid leukaemia in adults.

    Technology appraisal guidance
    Published
    21 December 2016
    View recommendations

    Sections for TA426

  9. What are the long-term outcomes, both psychotic and nonpsychotic, for children and young people with attenuated or transient psychotic symptoms suggestive of a developing psychosis, and can the criteria for 'at risk states' be refined to better predict those who will and those who will not go on to develop psychosis?

    programme of research would be in two phases. First, a systematic review and meta-analysis of prospective observational studies/cohorts...

    Research recommendation
    Published
    9 June 2015

  10. The Versajet II hydrosurgery system for surgical debridement of acute and chronic wounds and burns (MIB1)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Versajet II hydrosurgery system

    Medtech innovation briefing
    Published
    4 February 2014

  11. Age-related macular degeneration (NG82)

    This guideline covers diagnosing and managing age-related macular degeneration (AMD) in adults. It aims to improve the speed at which people are diagnosed and treated to prevent loss of sight.

    NICE guideline
    Published
    23 January 2018
    View recommendations

    Sections for NG82

  12. Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia (TA1013)

    Evidence-based recommendations on quizartinib (Vanflyta) for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia in adults.

    Technology appraisal guidance
    Published
    23 October 2024
    View recommendations

    Sections for TA1013

  13. Ultrasound-guided foam sclerotherapy for varicose veins (IPG440)

    Evidence-based recommendations on ultrasound guided foam sclerotherapy for varicose veins. This involves mixing a chemical with air or another gas to produce a foam, which is injected into the affected vein using ultrasound imaging to monitor its progress.

    Interventional procedures guidance
    Published
    23 February 2013
    View recommendations

    Sections for IPG440

  14. Transapical transcatheter mitral valve-in-ring implantation after failed annuloplasty for mitral valve repair (IPG707)

    Evidence-based recommendations on transapical transcatheter mitral valve-in-ring implantation after failed annuloplasty for mitral valve repair in adults. This involves inserting a bioprosthetic mitral valve into an existing mitral valve ring to treat a leaking mitral valve, without needing repeat open heart surgery.

    Interventional procedures guidance
    Published
    22 September 2021
    View recommendations

    Sections for IPG707

  15. Chronic wounds: advanced wound dressings and antimicrobial dressings (ESMPB2)

    Summary of the evidence on advanced wound dressings and antimicrobial dressings for managing chronic wounds to inform local NHS planning and decision-making

    Evidence summary
    Published
    30 March 2016